[EN] NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY [FR] NOUVEAUX COMPOSÉS DE SULFONYLURÉE SUBSTITUÉS EN TANT QU'INHIBITEURS DE L'ACTIVITÉ DE L'INTERLEUKINE-1
摘要:
This application relates to novel substituted sulfonylurea compounds and analogues, their manufacture, pharmaceutical compositions comprising them, and their use as medicaments for treating a disease associated with modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3, or inhibition of the activation of NLRP3 or related components of the inflammatory process.
SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
申请人:F. Hoffmann-La Roche AG
公开号:EP3823974A1
公开(公告)日:2021-05-26
NLRP3 INHIBITORS
申请人:Inflazome Limited
公开号:EP3883646A1
公开(公告)日:2021-09-29
[EN] SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY<br/>[FR] COMPOSÉS DE SULFONIMIDAMIDE EN TANT QU'INHIBITEURS DE L'ACTIVITÉ DE L'INTERLEUKINE 1
申请人:GENENTECH INC
公开号:WO2020018975A1
公开(公告)日:2020-01-23
The present disclosure relates to novel sulfonimidamide compounds and related compounds and their use in treating a disorder responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process. (I)